

Detailed Contents

Chapter 1		
Nucleic Acid Structure and Gene Expression	1	
1.1 DNA, RNA, AND POLYPEPTIDES	2	
Most genetic information flows in the sequence		
DNA → RNA → polypeptide	2	
Nucleic acids and polypeptides are linear sequences of simple repeat units	3	
Nucleic acids	3	
Polypeptides	4	
The type of chemical bonding determines stability and function	6	
1.2 NUCLEIC ACID STRUCTURE AND DNA REPLICATION	7	
DNA and RNA structure	7	
Replication is semi-conservative and semi-discontinuous	9	
DNA polymerases sometimes work in DNA repair and recombination	9	
Many viruses have RNA genomes	11	
1.3 RNA TRANSCRIPTION AND GENE EXPRESSION	12	
Most genes are expressed to make polypeptides	14	
Different sets of RNA genes are transcribed by the three eukaryotic RNA polymerases	15	
1.4 RNA PROCESSING	16	
RNA splicing removes unwanted sequences from the primary transcript	16	
Specialized nucleotides are added to the ends of most RNA polymerase II transcripts	17	
5' capping	18	
3' polyadenylation	18	
rRNA and tRNA transcripts undergo extensive processing	19	
1.5 TRANSLATION, POST-TRANSLATIONAL PROCESSING, AND PROTEIN STRUCTURE	20	
mRNA is decoded to specify polypeptides	20	
The genetic code is degenerate and not quite universal	22	
Post-translational processing: chemical modification of amino acids and polypeptide cleavage	23	
Addition of carbohydrate groups	23	
Addition of lipid groups	24	
Post-translational cleavage	24	
The complex relationship between amino acid sequence and protein structure	25	
The α -helix	25	
The β -pleated sheet	26	
The β -turn	27	
Higher-order structures	27	
FURTHER READING	27	
Chapter 2		
Chromosome Structure and Function	29	
2.1 PLOIDY AND THE CELL CYCLE	30	
2.2 MITOSIS AND MEIOSIS	31	
Mitosis is the normal form of cell division	31	
Meiosis is a specialized reductive cell division that gives rise to sperm and egg cells	33	
Independent assortment	34	
Recombination	34	
X-Y pairing	35	
Mitosis and meiosis have key similarities and differences	36	
2.3 STRUCTURE AND FUNCTION OF CHROMOSOMES	36	
Chromosomal DNA is coiled hierarchically	36	
Interphase chromatin varies in its degree of compaction	38	
Each chromosome has its own territory in the interphase nucleus	38	
Centromeres have a pivotal role in chromosome movement but have evolved to be very different in different organisms	39	
Replication of a mammalian chromosome involves the flexible use of multiple replication origins	40	
Telomeres have specialized structures to preserve the ends of linear chromosomes	41	
Telomere structure, function, and evolution	41	
Telomerase and the chromosome end-replication problem	42	
2.4 STUDYING HUMAN CHROMOSOMES	43	
Chromosome analysis is easier for mitosis than meiosis	44	
Chromosomes are identified by size and staining pattern	44	
Chromosome banding	44	

Reporting of cytogenetic analyses	45	Mosaics	77
Molecular cytogenetics locates specific DNA sequences on chromosomes	46	Chimeras	78
Chromosome fluorescence <i>in situ</i> hybridization (FISH)	47	3.4 GENETICS OF MULTIFACTORIAL CHARACTERS: THE POLYGENIC THRESHOLD THEORY	79
Chromosome painting and molecular karyotyping	47	In the early twentieth century there was controversy between proponents of Mendelian and quantitative models of inheritance	79
Comparative genome hybridization (CGH)	48	Polygenic theory explains how quantitative traits can be genetically determined	79
2.5 CHROMOSOME ABNORMALITIES	50	Regression to the mean	80
Numerical chromosomal abnormalities involve gain or loss of complete chromosomes	50	Hidden assumptions	81
Polyploidy	50	Heritability measures the proportion of the overall variance of a character that is due to genetic differences	81
Aneuploidy	50	Misunderstanding heritability	82
Mixoploidy	51	The threshold model extended polygenic theory to cover dichotomous characters	82
Clinical consequences	52	Using threshold theory to understand recurrence risks	82
A variety of structural chromosomal abnormalities result from misrepair or recombination errors	53	Counseling in non-Mendelian conditions is based on empiric risks	83
Different factors contribute to the clinical consequences of structural chromosome abnormalities	55	3.5 FACTORS AFFECTING GENE FREQUENCIES	84
Incorrect parental origins of chromosomes can result in aberrant development and disease	56	A thought experiment: picking genes from the gene pool	84
CONCLUSION	58	The Hardy–Weinberg distribution relates genotype frequencies to gene frequencies	84
FURTHER READING	59	Using the Hardy–Weinberg relationship in genetic counseling	84
Chapter 3		Inbreeding	85
Genes in Pedigrees and Populations	61	Other causes of departures from the Hardy–Weinberg relationship	86
3.1 MONOGENIC VERSUS MULTIFACTORIAL INHERITANCE	62	Gene frequencies can vary with time	87
3.2 MENDELIAN PEDIGREE PATTERNS	64	Estimating mutation rates	88
There are five basic Mendelian pedigree patterns	64	The importance of heterozygote advantage	88
X-inactivation	65	CONCLUSION	89
Mosaicism due to X-inactivation	66	FURTHER READING	89
Few genes on the Y chromosome	67	Chapter 4	
Genes in the pseudoautosomal region	67	Cells and Cell–Cell Communication	91
Conditions caused by mutations in the mitochondrial DNA	68	4.1 CELL STRUCTURE AND DIVERSITY	92
The mode of inheritance can rarely be defined unambiguously in a single pedigree	69	Prokaryotes and eukaryotes represent a fundamental division of cellular life forms	92
Getting the right ratios: the problem of bias of ascertainment	69	The extraordinary diversity of cells in the body	93
The relation between Mendelian characters and gene sequences	70	Germ cells are specialized for reproductive functions	93
Locus heterogeneity	71	Cells in an individual multicellular organism can differ in DNA content	96
Clinical heterogeneity	72	4.2 CELL ADHESION AND TISSUE FORMATION	97
3.3 COMPLICATIONS TO THE BASIC MENDELIAN PEDIGREE PATTERNS	72	Cell junctions regulate the contact between cells	98
A common recessive condition can mimic a dominant pedigree pattern	72	Tight junctions	98
A dominant condition may fail to manifest itself	73	Anchoring cell junctions	99
Age-related penetrance in late-onset diseases	73	Communicating cell junctions	99
Many conditions show variable expression	74	The extracellular matrix regulates cell behavior as well as acting as a scaffold to support tissues	99
Anticipation	74	Specialized cell types are organized into tissues	100
Imprinting	75	Epithelium	100
Male lethality may complicate X-linked pedigrees	76	Connective tissue	101
Inbreeding can complicate pedigree interpretation	76	Muscle tissue	101
New mutations and mosaicism complicate pedigree interpretation	76	Nervous tissue	101

4.3 PRINCIPLES OF CELL SIGNALING 102
 Signaling molecules bind to specific receptors in responding cells to trigger altered cell behavior 102
 Some signaling molecules bind intracellular receptors that activate target genes directly 103
 Signaling through cell surface receptors often involves kinase cascades 105
 Signal transduction pathways often use small intermediate intracellular signaling molecules 106
 Synaptic signaling is a specialized form of cell signaling that does not require the activation of transcription factors 107

4.4 CELL PROLIFERATION, SENESCENCE, AND PROGRAMMED CELL DEATH 108
 Most of the cells in mature animals are non-dividing cells, but some tissues and cells turn over rapidly 108
 Mitogens promote cell proliferation by overcoming braking mechanisms that restrain cell cycle progression in G₁ 109
 Cell proliferation limits and the concept of cell senescence 111
 Large numbers of our cells are naturally programmed to die 111
 The importance of programmed cell death 112
 Apoptosis is performed by caspases in response to death signals or sustained cell stress 113
 Extrinsic pathways: signaling through cell surface death receptors 113
 Intrinsic pathways: intracellular responses to cell stress 113

4.5 STEM CELLS AND DIFFERENTIATION 114
 Cell specialization involves a directed series of hierarchical decisions 114
 Stem cells are rare self-renewing progenitor cells 115
 Tissue stem cells allow specific adult tissues to be replenished 115
 Stem cell niches 117
 Stem cell renewal versus differentiation 117
 Embryonic stem cells and embryonic germ cells are pluripotent 117
 Origins of cultured embryonic stem cells 118
 Pluripotency tests 119
 Embryonic germ cells 119

4.6 IMMUNE SYSTEM CELLS: FUNCTION THROUGH DIVERSITY 119
 The innate immune system provides a rapid response based on general pattern recognition of pathogens 121
 The adaptive immune system mounts highly specific immune responses that are enhanced by memory cells 122
 Humoral immunity depends on the activities of soluble antibodies 123
 In cell-mediated immunity, T cells recognize cells containing fragments of foreign proteins 125
 T-cell activation 127
 The unique organization and expression of Ig and TCR genes 128

Additional recombination and mutation mechanisms contribute to receptor diversity in B cells, but not T cells 130
 The monospecificity of Igs and TCRs is due to allelic exclusion and light chain exclusion 131
FURTHER READING 132

Chapter 5 Principles of Development 133

5.1 AN OVERVIEW OF DEVELOPMENT 134
 Animal models of development 135

5.2 CELL SPECIALIZATION DURING DEVELOPMENT 136
 Cells become specialized through an irreversible series of hierarchical decisions 136
 The choice between alternative cell fates often depends on cell position 137
 Sometimes cell fate can be specified by lineage rather than position 138

5.3 PATTERN FORMATION IN DEVELOPMENT 139
 Emergence of the body plan is dependent on axis specification and polarization 139
 Pattern formation often depends on gradients of signaling molecules 141
 Homeotic mutations reveal the molecular basis of positional identity 142

5.4 MORPHOGENESIS 144
 Morphogenesis can be driven by changes in cell shape and size 144
 Major morphogenetic changes in the embryo result from changes in cell affinity 145
 Cell proliferation and apoptosis are important morphogenetic mechanisms 145

5.5 EARLY HUMAN DEVELOPMENT: FERTILIZATION TO GASTRULATION 146
 During fertilization the egg is activated to form a unique individual 146
 Cleavage partitions the zygote into many smaller cells 147
 Mammalian eggs are among the smallest in the animal kingdom, and cleavage in mammals is exceptional in several ways 148
 Only a small percentage of the cells in the early mammalian embryo give rise to the mature organism 148
 Implantation 150
 Gastrulation is a dynamic process by which cells of the epiblast give rise to the three germ layers 151

5.6 NEURAL DEVELOPMENT 154
 The axial mesoderm induces the overlying ectoderm to develop into the nervous system 155
 Pattern formation in the neural tube involves the coordinated expression of genes along two axes 155
 Neuronal differentiation involves the combinatorial activity of transcription factors 157

5.7 GERM-CELL AND SEX DETERMINATION IN MAMMALS	158	In phage display, heterologous proteins are expressed on the surface of phage particles	179
Primordial germ cells are induced in the early mammalian embryo and migrate to the developing gonads	158	Eukaryotic gene expression is performed with greater fidelity in eukaryotic cell lines	180
Sex determination involves both intrinsic and positional information	159	Transient expression in insect cells by using baculovirus	181
5.8 CONSERVATION OF DEVELOPMENTAL PATHWAYS	160	Transient expression in mammalian cells	181
Many human diseases are caused by the failure of normal developmental processes	160	Stable expression in mammalian cells	181
Developmental processes are often highly conserved but some show considerable species differences	160	6.4 CLONING DNA <i>IN VITRO</i>: THE POLYMERASE CHAIN REACTION	182
FURTHER READING	161	PCR can be used to amplify a rare target DNA selectively from within a complex DNA population	183
Chapter 6		The cyclical nature of PCR leads to exponential amplification of the target DNA	183
Amplifying DNA: Cell-based DNA Cloning and PCR	163	Selective amplification of target sequences depends on highly specific binding of primer sequences	184
Cell-based DNA cloning	165	PCR is disadvantaged as a DNA cloning method by short lengths and comparatively low yields of product	185
The polymerase chain reaction (PCR)	165	A wide variety of PCR approaches have been developed for specific applications	186
6.1 PRINCIPLES OF CELL-BASED DNA CLONING	165	Allele-specific PCR	187
Manageable pieces of target DNA are joined to vector molecules by using restriction endonucleases and DNA ligase	166	Multiple target amplification and whole genome PCR methods	187
Basic DNA cloning in bacterial cells uses vectors based on naturally occurring extrachromosomal replicons	168	PCR mutagenesis	188
Cloning in bacterial cells uses genetically modified plasmid or bacteriophage vectors and modified host cells	169	Real-time PCR (qPCR)	189
Transformation is the key DNA fractionation step in cell-based DNA cloning	171	FURTHER READING	189
Recombinant DNA can be selectively purified after screening and amplifying cell clones with desired target DNA fragments	172	Chapter 7	
6.2 LARGE INSERT CLONING AND CLONING SYSTEMS FOR PRODUCING SINGLE-STRANDED DNA	172	Nucleic Acid Hybridization: Principles and Applications	191
Early large insert cloning vectors exploited properties of bacteriophage λ	173	7.1 PRINCIPLES OF NUCLEIC ACID HYBRIDIZATION	192
Large DNA fragments can be cloned in bacterial cells by using extrachromosomal low-copy-number replicons	174	In nucleic acid hybridization a known nucleic acid population interrogates an imperfectly understood nucleic acid population	192
Bacterial artificial chromosome (BAC) and fosmid vectors	174	Probe–target heteroduplexes are easier to identify after capture on a solid support	193
Bacteriophage P1 vectors and P1 artificial chromosomes	175	Denaturation and annealing are affected by temperature, chemical environment, and the extent of hydrogen bonding	194
Yeast artificial chromosomes (YACs) enable cloning of megabase fragments of DNA	175	Stringent hybridization conditions increase the specificity of duplex formation	195
Producing single-stranded DNA for use in DNA sequencing and <i>in vitro</i> site-specific mutagenesis	176	The kinetics of DNA reassociation is also dependent on the concentration of DNA	196
M13 vectors	176	7.2 LABELING OF NUCLEIC ACIDS AND OLIGONUCLEOTIDES	197
Phagemid vectors	177	Different classes of hybridization probe can be prepared from DNA, RNA, and oligonucleotide substrates	197
6.3 CLONING SYSTEMS DESIGNED FOR GENE EXPRESSION	178	Long nucleic acid probes are usually labeled by incorporating labeled nucleotides during strand synthesis	197
Large amounts of protein can be produced by expression cloning in bacterial cells	178	Labeling DNA by nick translation	198
		Random primed DNA labeling	198
		PCR-based strand synthesis labeling	198
		RNA labeling	198

Radioisotopes can be used to label nucleic acids but are short-lived and can be hazardous	199	Single-molecule sequencing	220
Fluorophores are commonly used in nonisotopic labeling of nucleic acids	200	Mircoarray-based DNA capture methods allow efficient resequencing	223
7.3 HYBRIDIZATION TO IMMOBILIZED TARGET NUCLEIC ACIDS	203	8.3 GENOME STRUCTURE ANALYSIS AND GENOME PROJECTS	224
Dot-blot hybridization offers rapid screening and often employs allele-specific oligonucleotide probes	203	Framework maps are needed for first time sequencing of complex genomes	225
Southern and northern blot hybridizations detect size-fractionated DNA and RNA	204	The linear order of genomic DNA clones in a contig matches their original subchromosomal locations	226
Southern blot hybridization	204	The Human Genome Project was an international endeavor and biology's first Big Project	228
Northern blot hybridization	204	The first human genetic maps were of low resolution and were constructed with mostly anonymous DNA markers	228
In an <i>in situ</i> hybridization test, sample DNA or RNA is immobilized within fixed chromosome or cell preparations	205	Physical maps of the human genome progressed from marker maps to clone contig maps	230
Chromosome <i>in situ</i> hybridization	205	The final sequencing phase of the Human Genome Project was a race to an early finish	231
Tissue <i>in situ</i> hybridization	206	Genome projects have also been conducted for a variety of model organisms	234
Hybridization can be used to screen bacterial colonies containing recombinant DNA	206	Powerful genome databases and browsers help to store and analyze genome data	235
7.4 MICROARRAY-BASED HYBRIDIZATION ASSAYS	207	Different computer programs are designed to predict and annotate genes within genome sequences	235
Microarray hybridization allows highly parallel hybridization assays using thousands of different immobilized probes	207	Obtaining accurate estimates for the number of human genes is surprisingly difficult	238
High-density oligonucleotide microarrays offer enormously powerful tools for analyzing complex RNA and DNA samples	208	8.4 BASIC GENE EXPRESSION ANALYSES	239
Affymetrix oligonucleotide microarrays	209	Principles of expression screening	239
Illumina oligonucleotide microarrays	209	Hybridization-based methods allow semi-quantitative and high-resolution screening of transcripts of individual genes	240
Microarray hybridization is used mostly in transcript profiling or assaying DNA variation	209	Hybridization-based methods for assaying transcript size and abundance	241
FURTHER READING	211	Tissue <i>in situ</i> hybridization	241
Chapter 8		Quantitative PCR methods are widely used for expression screening	241
Analyzing the Structure and Expression of Genes and Genomes	213	Specific antibodies can be used to track proteins expressed by individual genes	242
8.1 DNA LIBRARIES	214	Protein expression in cultured cells is often analyzed by using different types of fluorescence microscopy	244
Genomic DNA libraries comprise fragmented copies of all the different DNA molecules in a cell	214	8.5 HIGHLY PARALLEL ANALYSES OF GENE EXPRESSION	245
cDNA libraries comprise DNA copies of the different RNA molecules in a cell	214	DNA and oligonucleotide microarrays permit rapid global transcript profiling	245
To be useful, DNA libraries need to be conveniently screened and disseminated	215	Modern global gene expression profiling increasingly uses sequencing to quantitate transcripts	248
Library screening	215	Global protein expression is often profiled with two-dimensional gel electrophoresis and mass spectrometry	249
Library amplification and dissemination	216	Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE)	249
8.2 SEQUENCING DNA	217	Mass spectrometry	250
Dideoxy DNA sequencing involves enzymatic DNA synthesis using base-specific chain terminators	217	Comparative protein expression analyses have many applications	252
Automation of dideoxy DNA sequencing increased its efficiency	218	FURTHER READING	253
Iterative pyrosequencing records DNA sequences while DNA molecules are being synthesized	219		
Massively parallel DNA sequencing enables the simultaneous sequencing of huge numbers of different DNA fragments	220		
Massively parallel sequencing of amplified DNA	220		

Chapter 9		
Organization of the Human Genome	255	
9.1 GENERAL ORGANIZATION OF THE HUMAN GENOME	257	
The mitochondrial genome is densely packed with genetic information	257	
Replication of mitochondrial DNA	257	
Mitochondrial genes and their transcription	257	
The mitochondrial genetic code	258	
The human nuclear genome consists of 24 widely different chromosomal DNA molecules	260	
The human genome contains at least 26,000 genes, but the exact gene number is difficult to determine	261	
Human genes are unevenly distributed between and within chromosomes	263	
Duplication of DNA segments has resulted in copy-number variation and gene families	263	
Gene duplication mechanisms	263	
9.2 PROTEIN-CODING GENES	265	
Human protein-coding genes show enormous variation in size and internal organization	265	
Size variation	265	
Repetitive sequences within coding DNA	266	
Different proteins can be specified by overlapping transcription units	266	
Overlapping genes and genes-within-genes	266	
Genes divergently transcribed or co-transcribed from a common promoter	266	
Human protein-coding genes often belong to families of genes that may be clustered or dispersed on multiple chromosomes	268	
Different classes of gene family can be recognized according to the extent of sequence and structural similarity of the protein products	269	
Gene duplication events that give rise to multigene families also create pseudogenes and gene fragments	271	
9.3 RNA GENES	274	
More than 1000 human genes encode an rRNA or tRNA, mostly within large gene clusters	277	
Ribosomal RNA genes	277	
Transfer RNA genes	279	
Dispersed gene families make various small nuclear RNAs that facilitate general gene expression	280	
Spliceosomal small nuclear RNA (snRNA) genes	281	
Non-spliceosomal small nuclear RNA genes	282	
Small nucleolar RNA (snoRNA) genes	282	
Small Cajal body RNA genes	283	
Close to 1000 different human microRNAs regulate complex sets of target genes by base pairing to the RNA transcripts	283	
Many thousands of different piRNAs and endogenous siRNAs suppress transposition and regulate gene expression	285	
Piwi-protein-interacting RNA	285	
Endogenous siRNAs	286	
More than 3000 human genes synthesize a wide variety of medium-sized to large regulatory RNAs	287	
9.4 HIGHLY REPETITIVE DNA: HETEROCHROMATIN AND TRANSPOSON REPEATS	289	
Constitutive heterochromatin is largely defined by long arrays of high-copy-number tandem DNA repeats	289	
Transposon-derived repeats make up more than 40% of the human genome and arose mostly through RNA intermediates	290	
Human LTR transposons	291	
Human DNA transposon fossils	291	
A few human LINE-1 elements are active transposons and enable the transposition of other types of DNA sequence	291	
Alu repeats are the most numerous human DNA elements and originated as copies of 7SL RNA	292	
CONCLUSION	293	
FURTHER READING	294	
Chapter 10		
Model Organisms, Comparative Genomics, and Evolution	297	
10.1 MODEL ORGANISMS	298	
Unicellular model organisms aid understanding of basic cell biology and microbial pathogens	298	
Some invertebrate models offer cheap high-throughput genetic screening, and can sometimes model disease	301	
Various fish, frog, and bird models offer accessible routes to the study of vertebrate development	301	
Mammalian models are disadvantaged by practical limitations and ethical concerns	303	
Humans are the ultimate model organism and will probably be a principal one some time soon	305	
10.2 COMPARATIVE GENOMICS	306	
Evolutionary constraint and the preservation of function by purifying selection	306	
Rapidly evolving sequences and positive selection	308	
A variety of computer programs allow automated genome sequence alignments	308	
Comparative genomics helps validate predicted genes and identifies novel genes	309	
Comparative genomics reveals a surprisingly large amount of functional noncoding DNA in mammals	310	
Comparative genomics has been particularly important in identifying regulatory sequences	312	
10.3 GENE AND GENOME EVOLUTION	313	
Gene complexity is increased by exon duplication and exon shuffling	314	
Exon duplication	314	
Exon shuffling	315	
Gene duplication can permit increased gene dosage but its major value is to permit functional complexity	315	

The globin superfamily illustrates divergence in gene regulation and function after gene duplication	317	Elongation of the transcript	349
Two or three major whole genome duplication events have occurred in vertebrate lineages since the split from tunicates	318	Termination of transcription	349
Major chromosome rearrangements have occurred during mammalian genome evolution	319	Many other proteins modulate the activity of the basal transcription apparatus	349
In heteromorphic sex chromosomes, the smaller chromosome is limited to one sex and is mostly non-recombining with few genes	320	Sequence-specific DNA-binding proteins can bind close to a promoter or at more remote locations	350
The pseudoautosomal regions have changed rapidly during evolution	322	Co-activators and co-repressors influence promoters without binding to DNA	352
Human sex chromosomes evolved after a sex-determining locus developed on one autosome, causing it to diverge from its homolog	323	11.2 CHROMATIN CONFORMATION: DNA METHYLATION AND THE HISTONE CODE	353
Abundant testis-expressed genes on the Y chromosome are mostly maintained by intrachromosomal gene conversion	324	Modifications of histones in nucleosomes may comprise a histone code	353
X-chromosome inactivation developed in response to gene depletion from the Y chromosome	326	Open and closed chromatin	354
10.4 OUR PLACE IN THE TREE OF LIFE	326	ATP-dependent chromatin remodeling complexes	356
Molecular phylogenetics uses sequence alignments to construct evolutionary trees	326	DNA methylation is an important control in gene expression	357
Evolutionary trees can be constructed in different ways, and their reliability is tested by statistical methods	328	Methyl-CpG-binding proteins	358
The G-value paradox: organism complexity is not simply related to the number of (protein-coding) genes	329	DNA methylation in development	359
Striking lineage-specific gene family expansion often involves environmental genes	332	Chromatin states are maintained by several interacting mechanisms	360
Regulatory DNA sequences and other noncoding DNA have significantly expanded in complex metazoans	333	The role of HP1 protein	361
Mutations in <i>cis</i> -regulatory sequences lead to gene expression differences that underlie morphological divergence	333	A role for small RNA molecules	361
Lineage-specific exons and <i>cis</i> -regulatory elements can originate from transposable elements	335	A role for nuclear localization	361
Gene family expansion and gene loss/inactivation have occurred recently in human lineages, but human-specific genes are very rare	337	No single prime cause?	362
Comparative genomic and phenotype-led studies seek to identify DNA sequences important in defining humans	339	The ENCODE project seeks to give a comprehensive overview of transcription and its control	362
CONCLUSION	341	Transcription is far more extensive than previously imagined	362
FURTHER READING	342	Predicting transcription start sites	364
Chapter 11		11.3 EPIGENETIC MEMORY AND IMPRINTING	365
Human Gene Expression	345	Epigenetic memory depends on DNA methylation, and possibly on the polycomb and trithorax groups of proteins	365
11.1 PROMOTERS AND THE PRIMARY TRANSCRIPT	347	X-inactivation: an epigenetic change that is heritable from cell to daughter cell, but not from parent to child	365
Transcription by RNA polymerase II is a multi-step process	347	Initiating X-inactivation: the role of XIST	366
Defining the core promoter and transcription start site	347	Escaping X-inactivation	367
Assembling the basal transcription apparatus	348	At imprinted loci, expression depends on the parental origin	367
		Prader–Willi and Angelman syndromes are classic examples of imprinting in humans	368
		Two questions arise about imprinting: how is it done and why is it done?	370
		Paramutations are a type of transgenerational epigenetic change	370
		Some genes are expressed from only one allele but independently of parental origin	371
		11.4 ONE GENE—MORE THAN ONE PROTEIN	372
		Many genes have more than one promoter	372
		Alternative splicing allows one primary transcript to encode multiple protein isoforms	373
		RNA editing can change the sequence of the mRNA after transcription	374
		11.5 CONTROL OF GENE EXPRESSION AT THE LEVEL OF TRANSLATION	375
		Further controls govern when and where a mRNA is translated	375

The discovery of many small RNAs that regulate gene expression caused a paradigm shift in cell biology	376	The protein interactome provides an important gateway to systems biology	399
MicroRNAs as regulators of translation	376	Defining nucleic acid–protein interactions is critical to understanding how genes function	401
MicroRNAs and cancer	378	Mapping protein–DNA interactions <i>in vitro</i>	401
Some unresolved questions	378	Mapping protein–DNA interactions <i>in vivo</i>	402
CONCLUSION	378	CONCLUSION	403
FURTHER READING	379	FURTHER READING	404
Chapter 12		Chapter 13	
Studying Gene Function in the Post-Genome Era	381	Human Genetic Variability and Its Consequences	405
12.1 STUDYING GENE FUNCTION: AN OVERVIEW	382	13.1 TYPES OF VARIATION BETWEEN HUMAN GENOMES	406
Gene function can be studied at a variety of different levels	383	Single nucleotide polymorphisms are numerically the most abundant type of genetic variant	406
Gene expression studies	383	Both interspersed and tandem repeated sequences can show polymorphic variation	408
Gene inactivation and inhibition of gene expression	383	Short tandem repeat polymorphisms: the workhorses of family and forensic studies	408
Defining molecular partners for gene products	383	Large-scale variations in copy number are surprisingly frequent in human genomes	409
Genomewide analyses aim to integrate analyses of gene function	384	13.2 DNA DAMAGE AND REPAIR MECHANISMS	411
12.2 BIOINFORMATIC APPROACHES TO STUDYING GENE FUNCTION	384	DNA in cells requires constant maintenance to repair damage and correct errors	411
Sequence homology searches can provide valuable clues to gene function	385	The effects of DNA damage	413
Database searching is often performed with a model of an evolutionarily conserved sequence	386	DNA replication, transcription, recombination, and repair use multiprotein complexes that share components	415
Comparison with documented protein domains and motifs can provide additional clues to gene function	388	Defects in DNA repair are the cause of many human diseases	415
12.3 STUDYING GENE FUNCTION BY SELECTIVE GENE INACTIVATION OR MODIFICATION	389	Complementation groups	416
Clues to gene function can be inferred from different types of genetic manipulation	389	13.3 PATHOGENIC DNA VARIANTS	416
RNA interference is the primary method for evaluating gene function in cultured mammalian cells	390	Deciding whether a DNA sequence change is pathogenic can be difficult	416
Global RNAi screens provide a systems-level approach to studying gene function in cells	392	Single nucleotide and other small-scale changes are a common type of pathogenic change	417
Inactivation of genes in the germ line provides the most detailed information on gene function	392	Missense mutations	417
12.4 PROTEOMICS, PROTEIN–PROTEIN INTERACTIONS, AND PROTEIN–DNA INTERACTIONS	393	Nonsense mutations	418
Proteomics is largely concerned with identifying and characterizing proteins at the biochemical and functional levels	393	Changes that affect splicing of the primary transcript	419
Large-scale protein–protein interaction studies seek to define functional protein networks	395	Frameshifts	420
Yeast two-hybrid screening relies on reconstituting a functional transcription factor	396	Changes that affect the level of gene expression	421
Affinity purification–mass spectrometry is widely used to screen for protein partners of a test protein	397	Pathogenic synonymous (silent) changes	422
Suggested protein–protein interactions are often validated by co-immunoprecipitation or pull-down assays	398	Variations at short tandem repeats are occasionally pathogenic	422
		Dynamic mutations: a special class of pathogenic microsatellite variants	423
		Variants that affect dosage of one or more genes may be pathogenic	425
		13.4 MOLECULAR PATHOLOGY: UNDERSTANDING THE EFFECT OF VARIANTS	428
		The biggest distinction in molecular pathology is between loss-of-function and gain-of-function changes	428
		Allelic heterogeneity is a common feature of loss-of-function phenotypes	429

Loss-of-function mutations produce dominant phenotypes when there is haploinsufficiency	429	Lod scores of +3 and -2 are the criteria for linkage and exclusion (for a single test)	453
Dominant-negative effects occur when a mutated gene product interferes with the function of the normal product	431	For whole genome searches a genomewide threshold of significance must be used	455
Gain-of-function mutations often affect the way in which a gene or its product reacts to regulatory signals	432	14.4 MULTIPOINT MAPPING	455
Diseases caused by gain of function of G-protein-coupled hormone receptors	433	The CEPH families were used to construct marker framework maps	455
Allelic homogeneity is not always due to a gain of function	433	Multipoint mapping can locate a disease locus on a framework of markers	456
Loss-of-function and gain-of-function mutations in the same gene will cause different phenotypes	433	14.5 FINE-MAPPING USING EXTENDED PEDIGREES AND ANCESTRAL HAPLOTYPES	457
13.5 THE QUEST FOR GENOTYPE-PHENOTYPE CORRELATIONS	435	Autozygosity mapping can map recessive conditions efficiently in extended inbred families	457
The phenotypic effect of loss-of-function mutations depends on the residual level of gene function	435	Identifying shared ancestral chromosome segments allows high-resolution genetic mapping	459
Genotype-phenotype correlations are especially poor for conditions caused by mitochondrial mutations	436	14.6 DIFFICULTIES WITH STANDARD LOD SCORE ANALYSIS	460
Variability within families is evidence of modifier genes or chance effects	437	Errors in genotyping and misdiagnoses can generate spurious recombinants	461
CONCLUSION	438	Computational difficulties limit the pedigrees that can be analyzed	462
FURTHER READING	438	Locus heterogeneity is always a pitfall in human gene mapping	462
Chapter 14		Pedigree-based mapping has limited resolution	462
Genetic Mapping of Mendelian Characters	441	Characters with non-Mendelian inheritance cannot be mapped by the methods described in this chapter	463
14.1 THE ROLE OF RECOMBINATION IN GENETIC MAPPING	442	CONCLUSION	463
Recombinants are identified by genotyping parents and offspring for pairs of loci	442	FURTHER READING	464
The recombination fraction is a measure of the genetic distance between two loci	442	Chapter 15	
Recombination fractions do not exceed 0.5, however great the distance between two loci	445	Mapping Genes Conferring Susceptibility to Complex Diseases	467
Mapping functions define the relationship between recombination fraction and genetic distance	445	15.1 FAMILY STUDIES OF COMPLEX DISEASES	468
Chiasma counts give an estimate of the total map length	446	The risk ratio (λ) is a measure of familial clustering	468
Recombination events are distributed non-randomly along chromosomes, and so genetic map distances may not correspond to physical distances	446	Shared family environment is an alternative explanation for familial clustering	469
14.2 MAPPING A DISEASE LOCUS	448	Twin studies suffer from many limitations	469
Mapping human disease genes depends on genetic markers	448	Separated monozygotic twins	470
For linkage analysis we need informative meioses	449	Adoption studies are the gold standard for disentangling genetic and environmental factors	471
Suitable markers need to be spread throughout the genome	449	15.2 SEGREGATION ANALYSIS	471
Linkage analysis normally uses either fluorescently labeled microsatellites or SNPs as markers	450	Complex segregation analysis estimates the most likely mix of genetic factors in pooled family data	471
14.3 TWO-POINT MAPPING	451	15.3 LINKAGE ANALYSIS OF COMPLEX CHARACTERS	473
Scoring recombinants in human pedigrees is not always simple	451	Standard lod score analysis is usually inappropriate for non-Mendelian characters	473
Computerized lod score analysis is the best way to analyze complex pedigrees for linkage between Mendelian characters	452	Near-Mendelian families	473
		Non-parametric linkage analysis does not require a genetic model	474
		Identity by descent versus identity by state	474
		Affected sib pair analysis	474
		Linkage analysis of complex diseases has several weaknesses	475
		Significance thresholds	475
		Striking lucky	476
		An example: linkage analysis in schizophrenia	476

15.4 ASSOCIATION STUDIES AND LINKAGE DISEQUILIBRIUM	477	Mouse models have a special role in identifying human disease genes	503
Associations have many possible causes	477	16.2 THE VALUE OF PATIENTS WITH CHROMOSOMAL ABNORMALITIES	504
Association is quite distinct from linkage, except where the family and the population merge	479	Patients with a balanced chromosomal abnormality and an unexplained phenotype provide valuable clues for research	504
Association studies depend on linkage disequilibrium	479	X-autosome translocations are a special case	505
The size of shared ancestral chromosome segments	480	Rearrangements that appear balanced under the microscope are not always balanced at the molecular level	506
Studying linkage disequilibrium	481	Comparative genomic hybridization allows a systematic search for microdeletions and microduplications	507
The HapMap project is the definitive study of linkage disequilibrium across the human genome	481	Long-range effects are a pitfall in disease gene identification	508
The use of tag-SNPs	484	16.3 POSITION-INDEPENDENT ROUTES TO IDENTIFYING DISEASE GENES	509
15.5 ASSOCIATION STUDIES IN PRACTICE	484	A disease gene may be identified through knowing the protein product	509
Early studies suffered from several systematic weaknesses	485	A disease gene may be identified through the function or interactions of its product	509
The transmission disequilibrium test avoids the problem of matching controls	485	A disease gene may be identified through an animal model, even without positional information	511
Association can be more powerful than linkage studies for detecting weak susceptibility alleles	486	A disease gene may be identified by using characteristics of the DNA sequence	511
Case-control designs are a feasible alternative to the TDT for association studies	487	16.4 TESTING POSITIONAL CANDIDATE GENES	512
Special populations can offer advantages in association studies	488	For Mendelian conditions, a candidate gene is normally screened for mutations in a panel of unrelated affected patients	512
A new generation of genomewide association (GWA) studies has finally broken the logjam in complex disease research	488	Epigenetic changes might cause a disease without changing the DNA sequence	513
The size of the relative risk	490	The gene underlying a disease may not be an obvious one	514
15.6 THE LIMITATIONS OF ASSOCIATION STUDIES	491	Locus heterogeneity is the rule rather than the exception	514
The common disease–common variant hypothesis proposes that susceptibility factors have ancient origins	491	Further studies are often necessary to confirm that the correct gene has been identified	515
The mutation–selection hypothesis suggests that a heterogeneous collection of recent mutations accounts for most disease susceptibility	492	16.5 IDENTIFYING CAUSAL VARIANTS FROM ASSOCIATION STUDIES	515
A complete account of genetic susceptibility will require contributions from both the common disease–common variant and mutation–selection hypotheses	493	Identifying causal variants is not simple	516
CONCLUSION	494	Causal variants are identified through a combination of statistical and functional studies	516
FURTHER READING	495	Functional analysis of SNPs in sequences with no known function is particularly difficult	518
Chapter 16		Calpain-10 and type 2 diabetes	518
Identifying Human Disease Genes and Susceptibility Factors	497	Chromosome 8q24 and susceptibility to prostate cancer	518
16.1 POSITIONAL CLONING	498	16.6 EIGHT EXAMPLES OF DISEASE GENE IDENTIFICATION	519
Positional cloning identifies a disease gene from its approximate chromosomal location	499	Case study 1: Duchenne muscular dystrophy	519
The first step in positional cloning is to define the candidate region as tightly as possible	500	Case study 2: cystic fibrosis	520
The second step is to establish a list of genes in the candidate region	500	Case study 3: branchio-oto-renal syndrome	522
The third step is to prioritize genes from the candidate region for mutation testing	501	Case study 4: multiple sulfatase deficiency	522
Appropriate expression	501	Case study 5: persistence of intestinal lactase	523
Appropriate function	502	Case study 6: CHARGE syndrome	525
Homologies and functional relationships	502	Case study 7: breast cancer	526
		Case study 8: Crohn disease	528

16.7 HOW WELL HAS DISEASE GENE IDENTIFICATION WORKED?	531	ATM: the initial detector of damage	555
Most variants that cause Mendelian disease have been identified	531	Nibrin and the MRN complex	555
Genomewide association studies have been very successful, but identifying the true functional variants remains difficult	532	CHEK2: a mediator kinase	555
Clinically useful findings have been achieved in a few complex diseases	532	The role of BRCA1/2	556
Alzheimer disease	532	p53 to the rescue	556
Age-related macular degeneration (ARMD)	533	Defects in the repair machinery underlie a variety of cancer-prone genetic disorders	556
Eczema (atopic dermatitis)	533	Microsatellite instability was discovered through research on familial colon cancer	557
The problem of hidden heritability	534	17.6 GENOMEWIDE VIEWS OF CANCER	559
CONCLUSION	534	Cytogenetic and microarray analyses give genomewide views of structural changes	559
FURTHER READING	535	New sequencing technologies allow genomewide surveys of sequence changes	559
 		Further techniques provide a genomewide view of epigenetic changes in tumors	560
Chapter 17		Genomewide views of gene expression are used to generate expression signatures	560
Cancer Genetics	537	17.7 UNRAVELING THE MULTI-STAGE EVOLUTION OF A TUMOR	561
17.1 THE EVOLUTION OF CANCER	539	The microevolution of colorectal cancer has been particularly well documented	561
17.2 ONCOGENES	540	17.8 INTEGRATING THE DATA: CANCER AS CELL BIOLOGY	564
Oncogenes function in growth signaling pathways	541	Tumorigenesis should be considered in terms of pathways, not individual genes	564
Oncogene activation involves a gain of function	542	Malignant tumors must be capable of stimulating angiogenesis and metastasizing	565
Activation by amplification	542	Systems biology may eventually allow a unified overview of tumor development	566
Activation by point mutation	543	CONCLUSION	566
Activation by a translocation that creates a novel chimeric gene	543	FURTHER READING	567
Activation by translocation into a transcriptionally active chromatin region	544	 	
Activation of oncogenes is only oncogenic under certain circumstances	546	Chapter 18	
17.3 TUMOR SUPPRESSOR GENES	546	Genetic Testing of Individuals	569
Retinoblastoma provided a paradigm for understanding tumor suppressor genes	546	18.1 WHAT TO TEST AND WHY	571
Some tumor suppressor genes show variations on the two-hit paradigm	547	Many different types of sample can be used for genetic testing	571
Loss of heterozygosity has been widely used as a marker to locate tumor suppressor genes	548	RNA or DNA?	572
Tumor suppressor genes are often silenced epigenetically by methylation	549	Functional assays	572
17.4 CELL CYCLE DYSREGULATION IN CANCER	550	18.2 SCANNING A GENE FOR MUTATIONS	572
Three key tumor suppressor genes control events in G ₁ phase	551	A gene is normally scanned for mutations by sequencing	573
pRb: a key regulator of progression through G ₁ phase	551	A variety of techniques have been used to scan a gene rapidly for possible mutations	574
p53: the guardian of the genome	551	Scanning methods based on detecting mismatches or heteroduplexes	574
CDKN2A: one gene that encodes two key regulatory proteins	552	Scanning methods based on single-strand conformation analysis	576
17.5 INSTABILITY OF THE GENOME	553	Scanning methods based on translation: the protein truncation test	576
Various methods are used to survey cancer cells for chromosomal changes	553	Microarrays allow a gene to be scanned for almost any mutation in a single operation	576
Three main mechanisms are responsible for the chromosome instability and abnormal karyotypes	553	DNA methylation patterns can be detected by a variety of methods	577
Telomeres are essential for chromosomal stability	554	Unclassified variants are a major problem	578
DNA damage sends a signal to p53, which initiates protective responses	555		

18.3 TESTING FOR A SPECIFIED SEQUENCE CHANGE 579

Testing for the presence or absence of a restriction site	579
Allele-specific oligonucleotide hybridization	580
Allele-specific PCR amplification	581
The oligonucleotide ligation assay	581
Minisequencing by primer extension	581
Pyrosequencing	583
Genotyping by mass spectrometry	583
Array-based massively parallel SNP genotyping	583

18.4 SOME SPECIAL TESTS 585

Testing for whole-exon deletions and duplications requires special techniques	585
The multiplex ligation-dependent probe amplification (MLPA) test	585
Dystrophin gene deletions in males	586
Apparent non-maternity in a family in which a deletion is segregating	587
A quantitative PCR assay is used in prenatal testing for fetal chromosomal aneuploidy	587
Some triplet repeat diseases require special tests	588
The mutation screen for some diseases must take account of geographical variation	589
Testing for diseases with extensive locus heterogeneity is a challenge	590

18.5 GENE TRACKING 592

Gene tracking involves three logical steps	592
Recombination sets a fundamental limit on the accuracy of gene tracking	593
Calculating risks in gene tracking	594
Bayesian calculations	594
Using linkage programs for calculating genetic risks	595
The special problems of Duchenne muscular dystrophy	595

18.6 DNA PROFILING 596

A variety of different DNA polymorphisms have been used for profiling	596
DNA fingerprinting using minisatellite probes	596
DNA profiling using microsatellite markers	597
Y-chromosome and mitochondrial polymorphisms	597
DNA profiling is used to disprove or establish paternity	598
DNA profiling can be used to identify the origin of clinical samples	598
DNA profiling can be used to determine the zygosity of twins	598
DNA profiling has revolutionized forensic investigations but raises issues of civil liberties	599
Technical issues	599
Courtroom issues	600
Ethical and political issues	601

CONCLUSION 602

FURTHER READING 603

Chapter 19 Pharmacogenetics, Personalized Medicine, and Population Screening 605

19.1 EVALUATION OF CLINICAL TESTS 606

The analytical validity of a test is a measure of its accuracy	606
The clinical validity of a test is measured by how well it predicts a clinical condition	607
Tests must also be evaluated for their clinical utility and ethical acceptability	608

19.2 PHARMACOGENETICS AND PHARMACOGENOMICS 609

Many genetic differences affect the metabolism of drugs	610
The P450 cytochromes are responsible for much of the phase 1 metabolism of drugs	610
CYP2D6	611
Other P450 enzymes	612
Another phase 1 enzyme variant causes a problem in surgery	613
Phase 2 conjugation reactions produce excretable water-soluble derivatives of a drug	613
Fast and slow acetylators	613
UGT1A1 glucuronosyltransferase	614
Glutathione S-transferase GSTM1, GSTT1	614
Thiopurine methyltransferase	614
Genetic variation in its target can influence the pharmacodynamics of a drug	614
Variants in beta-adrenergic receptors	614
Variations in the angiotensin-converting enzyme	615
Variations in the HT2RA serotonin receptor	615
Malignant hyperthermia and the ryanodine receptor	616

19.3 PERSONALIZED MEDICINE: PRESCRIBING THE BEST DRUG 616

Without bedside genotyping it is difficult to put the ideal into practice	616
Drug effects are often polygenic	616
Warfarin	617
Pharmaceutical companies have previously had little incentive to promote personalized medicine	618
The stages in drug development	618
Some drugs are designed or licensed for treating patients with specific genotypes	619
Trastuzumab for breast cancer with HER2 amplification	619
Gefitinib for lung and other cancers that have EGFR mutations	620
Expression profiling of tumors may lead to personalized treatment	620
An alternative approach: depersonalized medicine and the polypill	621

19.4 PERSONALIZED MEDICINE: TESTING FOR SUSCEPTIBILITY TO COMPLEX DISEASES 622

Researchers are finally able to identify genetic susceptibility factors	622
Individual factors are almost always weak	622

Even if no single test gives a strong prediction, maybe a battery of tests will	623	Nuclear transfer has been used to produce genetically modified domestic mammals	646
Much remains unknown about the clinical validity of susceptibility tests	624	Exogenous promoters provide a convenient way of regulating transgene expression	646
Risk of type 2 diabetes: the Framingham and Scandinavian studies	625	Tetracycline-regulated inducible transgene expression	647
Risk of breast cancer: the study of Pharoah and colleagues	625	Tamoxifen-regulated inducible transgene expression	647
Risk of prostate cancer: the study of Zheng and colleagues	627	Transgene expression may be influenced by position effects and locus structure	648
Evidence on the clinical utility of susceptibility testing is almost wholly lacking	627	20.3 TARGETED GENOME MODIFICATION AND GENE INACTIVATION <i>IN VIVO</i>	648
19.5 POPULATION SCREENING	628	The isolation of pluripotent ES cell lines was a landmark in mammalian genetics	648
Screening tests are not diagnostic tests	629	Gene targeting allows the production of animals carrying defined mutations in every cell	649
Prenatal screening for Down syndrome defines an arbitrary threshold for diagnostic testing	629	Different gene-targeting approaches create null alleles or subtle point mutations	650
Acceptable screening programs must fit certain criteria	631	Gene knockouts	650
What would screening achieve?	631	Gene knock-ins	650
Sensitivity and specificity	631	Creating point mutations	651
Choosing subjects for screening	633	Microbial site-specific recombination systems allow conditional gene inactivation and chromosome engineering in animals	651
An ethical framework for screening	633	Conditional gene inactivation	653
Some people worry that prenatal screening programs might devalue and stigmatize affected people	633	Chromosome engineering	653
Some people worry that enabling people with genetic diseases to lead normal lives spells trouble for future generations	634	Zinc finger nucleases offer an alternative way of performing gene targeting	654
19.6 THE NEW PARADIGM: PREDICT AND PREVENT?	634	Targeted gene knockdown at the RNA level involves cleaving the gene transcripts or inhibiting their translation	656
CONCLUSION	636	<i>In vivo</i> gene knockdown by RNA interference	656
FURTHER READING	637	Gene knockdown with morpholino antisense oligonucleotides	656
Chapter 20		20.4 RANDOM MUTAGENESIS AND LARGE-SCALE ANIMAL MUTAGENESIS SCREENS	657
Genetic Manipulation of Animals for Modeling Disease and Investigating Gene Function	639	Random mutagenesis screens often use chemicals that mutate bases by adding ethyl groups	658
20.1 OVERVIEW	640	Insertional mutagenesis can be performed in ES cells by using expression-defective transgenes as gene traps	658
A wide range of species are used in animal modeling	640	Transposons cause random insertional gene inactivation by jumping within a genome	658
Most animal models are generated by some kind of artificially designed genetic modification	640	Insertional mutagenesis with the Sleeping Beauty transposon	659
Multiple types of phenotype analysis can be performed on animal models	642	piggyBac-mediated transposition	660
20.2 MAKING TRANSGENIC ANIMALS	643	The International Mouse Knockout Consortium seeks to knock out all mouse genes	660
Transgenic animals have exogenous DNA inserted into the germ line	643	20.5 USING GENETICALLY MODIFIED ANIMALS TO MODEL DISEASE AND DISSECT GENE FUNCTION	661
Pronuclear microinjection is an established method for making some transgenic animals	644	Genetically modified animals have furthered our knowledge of gene function	661
Transgenes can also be inserted into the germ line via germ cells, gametes, or pluripotent cells derived from the early embryo	645	Creating animal models of human disease	662
Gene transfer into gametes and germ cell precursors	645	Loss-of-function mutations are modeled by selectively inactivating the orthologous mouse gene	662
Gene transfer into pluripotent cells of the early embryo or cultured pluripotent stem cells	645	Null alleles	663
Gene transfer into somatic cells (animal cloning)	645	Humanized alleles	663

Leaky mutations and hypomorphs	663	21.4 PRINCIPLES OF GENE THERAPY AND MAMMALIAN GENE TRANSFECTION SYSTEMS	696
Gain-of-function mutations are conveniently modeled by expressing a mutant transgene	663	Genes can be transferred to a patient's cells either in culture or within the patient's body	699
Modeling chromosomal disorders is a challenge	666	Integration of therapeutic genes into host chromosomes has significant advantages but raises major safety concerns	700
Modeling human cancers in mice is complex	667	Viral vectors offer strong and sometimes long-term transgene expression, but many come with safety risks	700
Gene knockouts to model loss of tumor suppressor function	668	Retroviral vectors	701
Transgenic mice to model oncogene activation	670	Adenoviral and adeno-associated virus (AAV) vectors	702
Modeling sporadic cancers	670	Other viral vectors	703
Humanized mice can overcome some of the species differences that make mice imperfect models	670	Non-viral vector systems are safer, but gene transfer is less efficient and transgene expression is often relatively weak	704
New developments in genetics are extending the range of disease models	671	Transfer of naked nucleic acid by direct injection or particle bombardment	704
CONCLUSION	672	Lipid-mediated gene transfer	704
FURTHER READING	673	Compacted DNA nanoparticles	704
Chapter 21		21.5 RNA AND OLIGONUCLEOTIDE THERAPEUTICS AND THERAPEUTIC GENE REPAIR	704
Genetic Approaches to Treating Disease	677	Therapeutic RNAs and oligonucleotides are often designed to selectively inactivate a mutant allele	705
21.1 TREATMENT OF GENETIC DISEASE VERSUS GENETIC TREATMENT OF DISEASE	678	Therapeutic ribozymes	706
Treatment of genetic disease is most advanced for disorders whose biochemical basis is well understood	678	Therapeutic siRNA	707
Genetic treatment of disease may be conducted at many different levels	679	Antisense oligonucleotides can induce exon skipping to bypass a harmful mutation	707
21.2 GENETIC APPROACHES TO DISEASE TREATMENT USING DRUGS, RECOMBINANT PROTEINS, AND VACCINES	680	Gene targeting with zinc finger nucleases can repair a specific pathogenic mutation or specifically inactivate a target gene	708
Drug companies have invested heavily in genomics to try to identify new drug targets	680	21.6 GENE THERAPY IN PRACTICE	709
Therapeutic proteins can be produced by expression cloning in microbes, mammalian cell lines, or transgenic animals	681	The first gene therapy successes involved recessively inherited blood cell disorders	710
Genetic engineering has produced novel antibodies with therapeutic potential	683	Gene therapies for many other monogenic disorders have usually had limited success	712
Aptamers are selected to bind to specific target proteins and inhibit their functions	685	Cancer gene therapies usually involve selective killing of cancer cells, but tumors can grow again by proliferation of surviving cells	713
Vaccines have been genetically engineered to improve their functions	686	Multiple HIV gene therapy strategies are being pursued, but progress toward effective treatment is slow	714
Cancer vaccines	687	CONCLUSION	715
21.3 PRINCIPLES AND APPLICATIONS OF CELL THERAPY	687	FURTHER READING	716
Stem cell therapies promise to transform the potential of transplantation	687		
Embryonic stem cells	688		
Tissue stem cells	688		
Practical difficulties in stem cell therapy	689		
Allogeneic and autologous cell therapy	689		
Nuclear reprogramming offers new approaches to disease treatment and human models of human disease	690		
Induced pluripotency in somatic cells	693		
Transdifferentiation	694		
Stem cell therapy has been shown to work but is at an immature stage	695		